Charles Schwab Investment Management Inc. Has $91.34 Million Position in Illumina, Inc. (NASDAQ:ILMN)

Charles Schwab Investment Management Inc. boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 4.0% during the 4th quarter, Holdings Channel reports. The institutional investor owned 683,545 shares of the life sciences company’s stock after buying an additional 25,991 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Illumina were worth $91,342,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bleakley Financial Group LLC acquired a new position in Illumina during the 4th quarter worth about $751,000. Zacks Investment Management acquired a new position in shares of Illumina in the 3rd quarter valued at about $2,924,000. Van ECK Associates Corp lifted its stake in shares of Illumina by 17.5% in the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company’s stock valued at $20,347,000 after purchasing an additional 22,718 shares during the period. Strategic Financial Concepts LLC acquired a new position in shares of Illumina in the 4th quarter valued at about $1,464,000. Finally, Allworth Financial LP lifted its stake in shares of Illumina by 720.7% in the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock valued at $1,001,000 after purchasing an additional 6,263 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ILMN has been the topic of a number of recent analyst reports. Morgan Stanley dropped their price objective on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 11th. Canaccord Genuity Group dropped their price objective on Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a research note on Friday, February 7th. Hsbc Global Res downgraded Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. HSBC downgraded Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective on the stock. in a research note on Friday, February 28th. Finally, Stephens boosted their target price on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $149.25.

Illumina Stock Performance

Shares of ILMN opened at $86.62 on Monday. The firm has a market capitalization of $13.72 billion, a P/E ratio of -11.28, a P/E/G ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The stock has a 50 day moving average price of $118.38 and a two-hundred day moving average price of $131.48. Illumina, Inc. has a 52 week low of $80.18 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities analysts forecast that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.